• Something wrong with this record ?

Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Y. Ye, M. Labopin, S. Gérard, I. Yakoub-Agha, IW. Blau, M. Aljurf, E. Forcade, T. Gedde-Dahl, D. Burns, J. Vydra, K. Halahleh, RM. Hamladji, A. Bazarbachi, A. Nagler, E. Brissot, L. Li, Y. Luo, Y. Zhao, F. Ciceri, H. Huang, M. Mohty, NC. Gorin

. 2024 ; 99 (7) : 1290-1299. [pub] 20240424

Language English Country United States

Document type Journal Article, Multicenter Study, Comparative Study

Persistent link   https://www.medvik.cz/link/bmc24013388

Grant support
82000180 National Natural Science Foundation of China
2021KY142 Medical Science and Technology Project of Zhejiang Province

Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry-based analysis the allo-HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo-HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo-HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB-MYH11 and 362 patients (42%) were t(8;21)/RUNX1-RUNX1T1 AML. On multivariate analysis, Haplo-HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32-0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33-0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF-AML with t(8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3-2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1-2.27; p < .01) than CBF-AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF-AML patients in CR2, Haplo-HCTs were associated with a lower RI compared to MSD and MUD allo-HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t(8;21) after allo-HCT in CR2.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013388
003      
CZ-PrNML
005      
20240905133306.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27342 $2 doi
035    __
$a (PubMed)38654658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ye, Yishan $u Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China $1 https://orcid.org/0000000337064959
245    10
$a Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation / $c Y. Ye, M. Labopin, S. Gérard, I. Yakoub-Agha, IW. Blau, M. Aljurf, E. Forcade, T. Gedde-Dahl, D. Burns, J. Vydra, K. Halahleh, RM. Hamladji, A. Bazarbachi, A. Nagler, E. Brissot, L. Li, Y. Luo, Y. Zhao, F. Ciceri, H. Huang, M. Mohty, NC. Gorin
520    9_
$a Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry-based analysis the allo-HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo-HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo-HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB-MYH11 and 362 patients (42%) were t(8;21)/RUNX1-RUNX1T1 AML. On multivariate analysis, Haplo-HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32-0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33-0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF-AML with t(8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3-2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1-2.27; p < .01) than CBF-AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF-AML patients in CR2, Haplo-HCTs were associated with a lower RI compared to MSD and MUD allo-HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t(8;21) after allo-HCT in CR2.
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x terapie $x genetika $7 D015470
650    12
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a sourozenci $7 D035781
650    12
$a nepříbuzný dárce $7 D061349
650    12
$a recidiva $7 D012008
650    _2
$a incidence $7 D015994
650    _2
$a senioři $7 D000368
650    _2
$a haploidentická transplantace $x metody $7 D000075442
650    _2
$a mladiství $7 D000293
650    _2
$a registrace $7 D012042
650    _2
$a transkripční faktor PEBP2 $x genetika $7 D050660
650    _2
$a mladý dospělý $7 D055815
650    _2
$a indukce remise $7 D012074
650    _2
$a alografty $7 D064591
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Labopin, Myriam $u EBMT Paris Study Office, Hôpital Saint Antoine 184, Paris Cedex 12, France
700    1_
$a Gérard, Socié $u Saint-Louis Hospital, BMT Unit, Paris, France
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ de Lille, INSERM U1286, Lille, France
700    1_
$a Blau, Igor Wolfgang $u Department of Hematology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
700    1_
$a Aljurf, Mahmoud $u King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
700    1_
$a Forcade, Edouard $u CHU Bordeaux, Hopital Haut-Leveque, Bordeaux, France
700    1_
$a Gedde-Dahl, Tobias $u Oslo University Hospital, Rikshospitalet, Oslo, Norway
700    1_
$a Burns, David $u University Hospital Birmingham NHSTrust, Birmingham, UK
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Halahleh, Khalid $u King Hussein Cancer Centre Adult BMT Program, Amman, Jordan
700    1_
$a Hamladji, Rose-Marie $u Centre Pierre et Marie Curie, Alger, Algeria
700    1_
$a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000271714997
700    1_
$a Nagler, Arnon $u Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
700    1_
$a Brissot, Eolia $u EBMT Paris Study Office, Hôpital Saint Antoine 184, Paris Cedex 12, France $u Department of Hematology and Cell therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
700    1_
$a Li, Lin $u Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China $1 https://orcid.org/0000000168584004
700    1_
$a Luo, Yi $u Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
700    1_
$a Zhao, Yanmin $u Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
700    1_
$a Ciceri, Fabio $u Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy
700    1_
$a Huang, He $u Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
700    1_
$a Mohty, Mohamad $u EBMT Paris Study Office, Hôpital Saint Antoine 184, Paris Cedex 12, France $u Department of Hematology and Cell therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
700    1_
$a Gorin, Norbert Claude $u EBMT Paris Study Office, Hôpital Saint Antoine 184, Paris Cedex 12, France $u Department of Hematology and Cell therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France $1 https://orcid.org/0000000201085769
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 7 (2024), s. 1290-1299
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38654658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133300 $b ABA008
999    __
$a ok $b bmc $g 2143289 $s 1225254
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 7 $d 1290-1299 $e 20240424 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a 82000180 $p National Natural Science Foundation of China
GRA    __
$a 2021KY142 $p Medical Science and Technology Project of Zhejiang Province
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options